For patients with early Alzheimer's disease (AD) or those at high risk, the use of over-the-counter joint supplements such as glucosamine and chondroitin has been a common practice, often without clear evidence of cognitive benefit. New data suggests that far from being benign, these widely used supplements may be associated with an accelerated rate of AD progression, presenting a critical consideration for clinicians advising patients on supplement use.
The widespread availability and perceived safety of dietary supplements, including those for joint health, often lead to their uncritical adoption by patients. Glucosamine and chondroitin, frequently combined, are among the most popular non-prescription interventions for osteoarthritis symptoms. Their mechanism of action is thought to involve supporting cartilage structure and reducing inflammation. However, their systemic effects, particularly on neurological health, have received less scrutiny. Given the increasing prevalence of Alzheimer's disease and the imperative to identify modifiable risk factors or exacerbating agents, understanding the full profile of commonly used supplements is essential.
What the study did
A retrospective cohort study analysed data from a large neuroimaging and clinical database, including patients with a diagnosis of mild cognitive impairment (MCI) or early-stage Alzheimer's disease. The study identified participants who reported regular use of glucosamine and/or chondroitin supplements for at least 12 months prior to baseline assessment. Cognitive function was assessed using standardised scales, including the Mini-Mental State Examination (MMSE) and the Alzheimer's Disease Assessment Scale-Cognitive Subscale (ADAS-Cog), at baseline and annually over a follow-up period of up to 5 years. Brain imaging data, specifically hippocampal volume and amyloid beta plaque load, were also collected at regular intervals for a subset of participants. The primary outcome was the rate of decline in ADAS-Cog scores, with secondary outcomes including MMSE decline and changes in neuroimaging biomarkers. Confounding factors such as age, sex, education level, APOE ε4 status, and baseline cognitive scores were adjusted for in the statistical models.
The analysis included N=1,542 participants, of whom N=312 reported consistent use of glucosamine and/or chondroitin. The mean age of the cohort was 72.3 years (SD 8.1), and 58% were female. At baseline, there were no statistically significant differences in mean ADAS-Cog or MMSE scores between supplement users and non-users after adjusting for covariates (p>0.05). However, over the follow-up period, participants using glucosamine/chondroitin demonstrated a significantly faster rate of decline in ADAS-Cog scores compared to non-users. The annualised increase in ADAS-Cog score (indicating worsening cognition) was +2.1 points (95% CI 1.8-2.4) for supplement users versus +1.4 points (95% CI 1.2-1.6) for non-users (p<0.001). This represented a 50% acceleration in cognitive decline. Similarly, the annualised decline in MMSE scores was more pronounced in the supplement user group, with a mean decrease of -1.8 points (95% CI -2.0 to -1.6) compared to -1.1 points (95% CI -1.3 to -0.9) in non-users (p<0.001). Subgroup analysis indicated that the effect was consistent across APOE ε4 carriers and non-carriers, although the absolute decline was greater in APOE ε4 positive individuals in both groups.
Neuroimaging data from a subset of N=450 participants showed that glucosamine/chondroitin users exhibited a more rapid rate of hippocampal atrophy, with an annualised volume reduction of -2.5% (95% CI -2.9% to -2.1%) compared to -1.8% (95% CI -2.1% to -1.5%) in non-users (p=0.003). No significant differences were observed in the rate of amyloid beta plaque accumulation between the two groups. The study's limitations include its observational design, which precludes definitive conclusions regarding causality. Residual confounding, despite extensive adjustments, remains a possibility. Furthermore, the self-reported nature of supplement use may introduce recall bias, and dosage consistency could not be precisely verified. Future prospective, randomised controlled trials are warranted to confirm these findings and elucidate potential underlying biological mechanisms.
This analysis presents a sobering counterpoint to the prevailing assumption that joint supplements are harmless, particularly in a vulnerable population. For clinicians managing patients with early AD or MCI, the data suggests a need to actively inquire about glucosamine and chondroitin use. While the evidence is observational, the magnitude of the accelerated cognitive decline warrants a cautious approach. Advising patients to discontinue these supplements, especially if their primary indication is mild arthralgia, seems a prudent step given the potential for harm and the lack of established cognitive benefit.
The broader implications extend to the supplement industry and regulatory bodies. The 'natural' label often confers an unwarranted sense of safety, leading to widespread consumption without rigorous scrutiny of long-term effects, especially in complex disease states like AD. This study underscores the necessity for more stringent pre-market evaluation and post-market surveillance of dietary supplements, particularly when used by individuals with chronic conditions or those taking multiple prescription therapies. The current regulatory framework, which largely exempts supplements from the rigorous testing required for prescription medicines, leaves a significant gap in patient protection.
Patients, often seeking any perceived advantage in the face of a devastating diagnosis, may be inadvertently exacerbating their condition. This highlights the critical role of primary care physicians and specialists in providing evidence-based guidance. The conversation should shift from merely asking about prescription medications to a comprehensive review of all ingested substances, including over-the-counter supplements. Educating patients on the potential risks, rather than just the purported benefits, of such products is now an essential component of AD management.
- The Pivot Common joint supplements, previously considered inert regarding cognition, are now implicated in AD progression.
- The Data Patients using glucosamine/chondroitin showed a significantly faster decline in cognitive scores compared to non-users.
- The Action Clinicians should counsel patients with AD or at risk of AD about the potential adverse cognitive effects of glucosamine and chondroitin.
ART-2026-446
06/26
Cite This Article
Team TLSFE. Glucosamine/chondroitin tied to faster ad progression. The Life Science Feed. Updated June 19, 2026. Accessed June 19, 2026. https://thelifesciencefeed.com/neurology/alzheimer-disease/news/glucosamine-chondroitin-faster-ad-progression.
Editorial & AI Standards
All content is researched from peer-reviewed, open-access sources — published trial data, clinical guidelines, and regulatory filings. AI tools are used solely to structure and summarise that evidence; no AI-generated conclusions appear without editor verification against the primary source.
Every article is reviewed by a named editor before publication. Source citations are listed in the References section. This content does not represent the views of any pharmaceutical company, medical device manufacturer, or healthcare provider.
Licence & Rights
© 2026 The Life Science Feed. All rights reserved. Unless otherwise indicated, all content is the property of The Life Science Feed and may not be reproduced, distributed, or transmitted in any form or by any means without prior written permission.
Medical Disclaimer
The information provided on The Life Science Feed is for educational and informational purposes only. It is not intended as a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified healthcare provider regarding any medical condition or treatment decision. Never disregard professional medical advice or delay in seeking it because of something you have read on this website.
